Correction to:Molecular Psychiatry
Supplementary Figure 1 and Supplementary Tables 1–4 have been re-uploaded so as to reflect the versions supplied during proofs stage. The publisher apologizes for the error in versioning. The HTML version of the paper has been updated.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Fava, M., Freeman, M.P., Flynn, M. et al. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25, 1604 (2020). https://doi.org/10.1038/s41380-018-0311-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-018-0311-2
This article is cited by
-
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Neuropsychopharmacology (2020)
-
Advances in depression research: second special issue, 2020, with highlights on biological mechanisms, clinical features, co-morbidity, genetics, imaging, and treatment
Molecular Psychiatry (2020)
